Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 17, 2019

Food and beverage makers are gearing up to sell CBD-containing products, when allowed by regulators, including Lagunitas Brewing, which has developed a cannabis-infused IPA and a THC-based sparkling water, and Ben & Jerry’s, which plans to offer a CBD-infused ice cream. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40